Clinigen Announce Acquisition of Idis for £225m

The Clinigen Group have announced that they are acquiring Idis for £225 million. The acquisition with Idis, an unlicensed medicines supplier, will make the Clinigen Group the global leader in unlicensed medicines.  The ethical unlicensed supply market is estimated to be worth in excess of $5bn. Idis supplies unlicensed medicines predominantly on an exclusive basis

Continue Reading